Enterin Patents Novel Aminosterol ENT-03 Compounds and Compositions
The USPTO published patent application US20260098052A1 for Enterin, Inc., covering novel aminosterol ENT-03 compounds, compositions comprising the same, and methods of making and using the same. The inventors are Denise Barbut and Michael Zasloff. The application was filed December 10, 2025, under application number 19415736. The CPC classifications indicate therapeutic applications including nervous system conditions (A61P 25/00).
SNIPR Biome ApS - Treating and Preventing Microbial Infections
USPTO published patent application US20260098259A1 assigned to SNIPR Biome ApS, covering methods for treating microbial infections including acute conditions such as sepsis, septicemia, SIRS, and septic shock. The application also discloses methods for controlling microbiologically influenced corrosion (MIC) and biofouling in industrial or domestic systems.
Protein Purification Using Chemically Activated Carbon at 0.1-15 wt%
USPTO published patent application US20260098056A1 for a method of purifying proteins from fermentation-derived solutions using chemically activated carbon. The method involves contacting the solution with 0.1-15 wt% activated carbon at pH 4-12 and temperature 2-60°C. Inventors: Sebastian Schoof, Thomas Kaeding, Gabriele Iffland. Application filed October 6, 2025.
Mammalian Cell SHMT2 Reduction for Protein Production
USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated SHMT2 expression and methods for using such cells in recombinant protein production. The application names Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, and Trissa Borgschulte as inventors. Filing date was September 29, 2023, under application number 19112697.
AMD Treatment with VEGF Antagonist Dosing at 8 or 12 Weeks
USPTO published patent application US20260098085A1 titled 'Methods for Treating Age-Related Macular Degeneration.' The application covers methods for reducing treatment burden for patients with intraocular neovascular disorders by administering VEGF antagonists on 8-week and/or 12-week dosing schedules. Inventors include Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, and Andreas Weichselberger. The application was filed on June 25, 2025.
Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof
The USPTO has published patent application US20260097127A1 for multimeric T-cell modulatory polypeptides comprising immunomodulatory polypeptides and epitope-presenting Wilms tumor peptides. The application, filed October 6, 2025, names Saso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel III, and John F. Ross as inventors. The published application covers methods for modulating T-cell activity and immune responses using the disclosed polypeptides.
IL-8 Signal Inhibitor Composition for Prophylaxis or Treatment of IL-8 Related Diseases
USPTO published patent application US20260098086A1 on April 9, 2026, covering compositions for prophylaxis or treatment of IL-8 related diseases using IL-8 signal inhibitors and anti-IL-8 antibodies. The application was filed December 5, 2025, by inventors Ayako KAKIUCHI, Atsuhiko Kato, Shuji Hayashi, Izumi Yanagisawa, Ryo Konno, Sachiho Netsu, and Tadashi Sankai. The published application contains CPC classifications related to antibodies and therapeutic compositions.
Dosages of Emactuzumab for TGCT Treatment, SYNOX Therapeutics
The USPTO published patent application US20260098087A1 by SYNOX Therapeutics UK Limited covering dosage regimens of emactuzumab, an anti-CSF-1R antibody, for treating tenosynovial giant cell tumour (TGCT). The application, filed October 20, 2025, describes treatment regimes and methods using the colony stimulating factor-1 receptor-binding antibody. The application is now publicly available as part of the standard patent examination process.
Modified siRNA Targeting C9orf72 Gene for Neurological Disorder Treatment
USPTO published patent application US20260098264A1 for modified single- or double-stranded siRNA molecules targeting the C9orf72 gene for treatment of neurological disorders including amyotrophic lateral sclerosis and frontotemporal dementia. The application covers branched siRNA structures with nucleoside modifications, phosphorus stabilizing moieties, and methods for CNS delivery.
Genentech Modified CHO Cells for Therapeutic Protein Production
USPTO published patent application US20260098254A1 by Genentech, Inc. covering modified CHO cells for therapeutic protein production. The application claims methods, cells, and compositions where mammalian cells have reduced or eliminated activity of host cell proteins including lipases, esterases, and hydrolases. Application No. 19408114 was filed December 3, 2025.
siRNA Molecules Targeting ATXN3 Gene for Spinocerebellar Ataxia Treatment
The USPTO published patent application US20260098265A1 disclosing single- or double-stranded siRNA molecules targeting the ataxin-3 (ATXN3) gene for treatment of spinocerebellar ataxias, including spinocerebellar ataxia type 3. The application includes branched siRNA designs (di-branched, tri-branched, tetra-branched) with nucleoside modifications, 5' phosphorus stabilizing moieties, and methods for CNS delivery. The application was filed on September 28, 2023.
CRISPR/Cas9 Gene Editing Method for Beta-Amyloid Pathway Attenuation
USPTO published patent application US20260097136A1 filed by Wisconsin Alumni Research Foundation on November 12, 2025. The application covers CRISPR/Cas9 constructs designed for C-terminal truncation of human amyloid precursor protein (APP) to attenuate the beta-amyloid pathway implicated in Alzheimer's disease, along with methods of making and using such constructs. The publication provides public notice of the claimed gene-editing technology and its potential therapeutic applications in neurodegenerative disease. No enforceable rights are granted until a patent issues following examination.
CRISPR/Cpf1 Gene Editing Systems Using Recombinant AsCpf1 and LbCpf1 crRNA
The USPTO published patent application US20260098249A1 for Integrated DNA Technologies covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for CRISPR/Cpf1 endonuclease gene editing systems in mammalian cell lines. The application includes ribonucleoprotein complexes using length-truncated, chemically-modified, or dual-modified AsCpf1 crRNAs and methods for performing gene editing using these systems.
MITAKA HDGS Needleless Syringe, Multiple Doses, Apr 09
MITAKA HDGS Needleless Syringe, Multiple Doses, Apr 09
Monitoring Device with Optical and Vibration Sensors for Medicament Delivery
The USPTO published patent application US20260097169A1 for a monitoring device designed to attach to medicament delivery devices. The device uses an optical sensor and vibration sensor to detect when a dose activation element is manually operated and correlates sensor data to confirm correct dose setting. The inventors are William Cirillo. The application was filed on May 27, 2025.
Sealing Cap for Syringe Tip Patent Application US20260097170A1
USPTO published patent application US20260097170A1 by inventor Mirhac Dinc for a sealing cap for a syringe tip. The application, filed July 28, 2023, describes a housing with a connection portion and an insert-engagement portion containing a sealing insert with tip-engagement and housing-engagement portions. The public notice period allows interested parties to review the invention before potential grant.
Tip Cap for Medical Injection Device, US20260097171A1
USPTO published patent application US20260097171A1 for a tip cap designed to seal a fluid passageway in a medical injection device. The application, filed September 19, 2023, covers an elastomeric inner cap with a proximally extending skirt in sealing engagement with a medical container tip, enclosed within a rigid outer cap having a threaded portion. The invention classifies under CPC codes A61M 5/345 and related medical device categories.
Neurocatheters, Systems, and Methods of Use
USPTO published patent application US20260097183A1 for neurocatheter technology. The patent covers catheters with proximal and distal portions having different stiffness ratios (proximal portion stiffer than distal by at least 10x). The catheter is configured for intracranial vessel access without requiring a guide sheath. Inventors: Paul De Lipski, John Miller, Tony M. Chou, Stephanie Sharpe, Christina Van. Filing date: 2025-10-03.
Machine Proximate Nebulizer Respiratory Therapy System
The USPTO has published patent application US20260097172A1 for a machine proximate nebulizer respiratory therapy system. The application, filed on June 11, 2025, covers a nebulizer system with a cylindrical mixing chamber, impacting cap, and recirculation tube for delivering aerosolized medicaments in respiratory therapy. The invention aims to improve aerosol delivery efficiency by entraining aerosol into breathing gas and recirculating rain-out droplets.
Access Vascular Inc - Gradient Annealing Polymeric Catheters
USPTO published patent application US20260097181A1 for Access Vascular Inc covering gradient annealing methods for polymeric catheter components with spatially varying mechanical properties. The application claims methods for producing catheters with improved kink resistance by spatially varying annealing to balance patient comfort with insertion ease. Inventors include Daniel T. Donahue, Michael Bassett, and Matthew M. Mannarino.
Adjustable Endobronchial Valve, Expandable Struts, Microfibers
Adjustable Endobronchial Valve, Expandable Struts, Microfibers
Methods to Reconstruct Bone and Joint Surfaces in Femorotibial and Patellofemoral Joint
USPTO published patent application US20260096890A1 assigned to Subchondral Solutions, Inc. for methods of bone and joint surface reconstruction in femorotibial and patellofemoral joints. The application covers therapeutic approaches to joint defects designed to restore biomechanical function without full joint replacement. The invention leverages subchondral bone health in treating mammalian joint conditions.
Direct View Scleral Contact Lens for Laser Trabeculoplasty
The USPTO published patent application US20260096928A1 assigned to Ocular Instruments, Inc. covering a direct view scleral contact lens designed for use in direct selective laser trabeculoplasty (DSLT) procedures. The invention includes a lens body with an inferior light exit surface forming a compression annulus that contacts the patient's eye during laser treatment, plus a ring of alignment markers.
Micro Actuator for Inner Ear Injection and Sampling Surgery
USPTO published patent application US20260096931A1 for a micro actuator for inner ear injection and sampling surgery. The invention includes a microneedle puncture mechanism, driving and sensing module, high-precision linear driving module, end-effector mechanism module, endoscope camera module, and tension sensor for real-time monitoring. Inventors: He Zhang, Haiming Li, Jie Zhao. Filed January 16, 2025.
Heated Hydrocolloid Patches For Skin Blemish Treatment
USPTO published patent application US20260096932A1 for a heated hydrocolloid skin patch with thermochromic temperature indicator, filed December 2, 2025. The invention comprises an outer barrier layer, a hydrocolloid layer, and thermochromic material that indicates when the patch reaches a predetermined temperature. The technology is applicable to skin blemish and wound treatment products.
Covidien LP Dermal Patch for Wound Healing
Covidien LP filed patent application US20260096933A1 for a dermal patch system designed to support, protect, and medicate wounds during the healing process. The patch includes a support layer and medicament depot. The application was filed November 11, 2025, under application number 19386193.
Comfort Sleeve Patent For Male Incontinence
USPTO published patent application US20260096934A1 for a comfort sleeve designed for male incontinence. The device features a sleeve with outer and inner layers containing an absorbent material, with upper, lower, and contour compression zones each having elastic bands with varying elasticity to comfortably secure and shape the sleeve around the penis.
Elastic Member and Disposable Wearing Article Including Elastic Member
USPTO published patent application US20260096935A1 assigned to Daio Paper Corporation for an elastic member designed to create non-monotonous, appealing wrinkles when applied to disposable absorbent articles such as diapers. The invention includes a third joined portion row between first and second joined portion rows with intervals longer than the standard interval S1. The application (No. 19352087) was filed on October 7, 2025.
Cerebral Embolic Protection Selection Method For TAVI Procedures
USPTO published patent application US20260096795A1 for a cerebral embolic protection selection method for TAVI procedures. The invention determines whether to deploy a CEP device by retrieving and segmenting aortic valve images to identify plaque vulnerability, then evaluating blood flow dynamics to select appropriate protection. Inventors include Holger Schmitt, Michael Grass, Christian Haase, and others.
DOJ Consolidates Health Care Fraud Enforcement Under New Division
The DOJ announced creation of the National Fraud Enforcement Division (NFED) on April 7, 2026, consolidating the Tax Section, Health Care Fraud Unit, and Market, Government, and Consumer Fraud Unit under Assistant Attorney General Colin McDonald. The NFED will coordinate fraud enforcement across federal, state, tribal, and local authorities targeting schemes against taxpayer-funded programs.
OIG Advisory Opinion 25-11 on Medical Product Discount Compliance
Foley & Lardner LLP analyzed OIG Advisory Opinion 25-11, which provides guidance on structuring discount arrangements for medical products under the federal Anti-Kickback Statute. The advisory opinion offers detailed guidance on permissible discount practices and the requirements of the discount safe harbor. The analysis notes that while failure to precisely meet safe harbor requirements does not automatically violate the AKS, such arrangements lose guaranteed protection and become subject to OIG's facts and circumstances analysis.
CMS Proposes 2-4% Medicare Advantage Payment Changes, Risk Adjustment Updates, Audit Focus for 2027
CMS has issued its Advance Notice and related rulemaking for Medicare Advantage (MA) and Part D programs for plan year 2027, projecting a net payment increase of approximately 2% to 4% depending on final rate-setting. The proposals advance revised Hierarchical Condition Categories (HCCs), continue efforts to reduce coding intensity, and expand Risk Adjustment Data Validation (RADV) audits with increased scrutiny of diagnosis reporting and supporting documentation.
Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025
Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025
Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors for Cancer Treatment
USPTO published patent application US20260097019A1 disclosing trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors for treating cancer and inhibiting tumor growth and metastasis. Inventors: Kavitha Nellore and Subramanya Hosahalli. Application filed April 30, 2025.
Therapeutic Use of Aromatase Inhibitors and PARP Inhibitors for Treatment of Malignancies
USPTO published patent application US20260097020A1 covering methods for treating gliomas including glioblastoma using aromatase inhibitors such as letrozole, optionally combined with PARP inhibitors (olaparib, pamiparib, veliparib, or niraparib). The application was filed September 30, 2025 under application number 19345169. Inventors include Pankaj B. Desai, Aniruddha S. Karve, Bhavesh B. Gabani, Sidharth N. Gadgil, and Gary A. Gudelsky.
Unit Oral Dose Compositions of Ibuprofen and Famotidine for Acute Pain and Heartburn Reduction
The USPTO published patent application US20260097023A1 for unit oral dose compositions combining ibuprofen (50-400 mg) and famotidine (3-20 mg) designed to treat acute pain while reducing the severity or risk of heartburn and upset stomach. The formulation specifies that famotidine must dissolve faster than ibuprofen within 45 minutes of administration. The application was filed on December 2, 2025, by inventor Bernard Schachtel.
Stable Amlodipine Oral Liquid Formulations for Hypertension and CAD Treatment
USPTO published patent application US20260097025A1 for stable amlodipine oral liquid formulations filed by inventors Scott Brauer and Gerold L. Mosher. The application covers formulations containing amlodipine for treating hypertension and Coronary Artery Disease (CAD), with CPC classifications in A61K therapeutic preparations. The application was filed on June 17, 2025, under application number 19240194.
Buprenorphine Depot Formulation Controlled-Release Matrix
USPTO published patent application US20260097031A1 for a depot precursor formulation comprising a controlled-release matrix with an oxygen-containing organic solvent and at least 12% by weight buprenorphine or salts thereof. Inventors include Fredrik Tiberg, Ian Harwigsson, and Markus Johnsson. The application covers methods for pain management and opioid maintenance treatment.
Integrated Preparedness Plan Workshop, Seymour IN, April 13
The Indiana Department of Health announces an Integrated Preparedness Plan Workshop on April 13, 2026, from 10:00 AM to 2:00 PM at Redeemer Lutheran Church in Seymour, IN. The workshop aims to validate preparedness priorities, identify capability gaps, and incorporate lessons learned from real-world events. Intended audience includes Local Health Department Preparedness Coordinators, Healthcare Coalition Readiness and Response Coordinators, and other preparedness organizations.
Ether Lipids Hyperactivate Dendritic Cells - Corner Therapeutics
The USPTO published patent application US20260097111A1 by Corner Therapeutics, Inc. on April 9, 2026, covering ether lipid (ETL) and ether phospholipid (ETPL) compounds for hyperactivating mammalian dendritic cells, including compositions combined with pathogen recognition receptor agonists, antigens, and dendritic cells. The application was originally filed on October 18, 2023.
Liposomal Compositions With Anti-Cancer Agents, Tumor-Targeting Lipopeptides
The USPTO published patent application US20260096988A1 on April 9, 2026, filed by inventors Debabrata Mukhopadhyay, Vijay S. Madamsetty, and Krishnendu Pal. The application covers liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides, as well as nanodiamond complexes and particles as carriers for anti-cancer agents. This publication provides public notice of the intellectual property claims related to advanced drug delivery compositions for cancer treatment. The pharmaceutical and biotechnology industries should monitor this application for potential impacts on cancer therapeutics development.
Silicon Nanoparticle Delivery System for Controlled Release of Nucleic Acids Including siRNA and mRNA
The USPTO published patent application US20260096997A1 assigned to SISAF LIMITED, filed November 6, 2025. The application covers a composition for controlled release of nucleic acids such as short interfering RNA (siRNA) or messenger RNA (mRNA), comprising silicon nanoparticles comprising at least 50% by weight silicon, at least one amino acid, and at least one lipid. The CPC classifications indicate primary focus on pharmaceutical preparations (A61K) and therapeutic uses including ophthalmological applications (A61P 27/02).
Modified oHSV with HRG for Cancer Therapy
The USPTO published patent application US20260097088A1 for a modified oncolytic herpes simplex virus (oHSV) engineered with an expression cassette encoding histidine-rich glycoprotein (HRG) for use in cancer therapy. The invention, filed on August 17, 2023 (Application No. 19113359), leverages virotherapy to selectively target and lyse cancer cells while sparing normal cells. The inventors are Chun-Yu Chen, Pin-Yi Wang, and Timothy P. Cripe.
Herbal Medicine Extracts RM01 for Alzheimer's Treatment
The USPTO has published patent application US20260097090A1, filed September 26, 2023, and published April 9, 2026, covering herbal extract compositions for treating neurodegenerative diseases including Alzheimer's disease. The composition includes extracts from Ophiopogon japonicus, Barbary Wolfberry, Rhizoma Acori tatarinowii, and Codonopsis pilosula. This is a patent application publication, not a granted patent, and does not confer any regulatory approval for the claimed treatments.
Parsnip Extract Composition for Intestinal Health and Leaky Gut Treatment
USPTO published patent application US20260097089A1 for a composition containing parsnip extract as an active ingredient. The composition is designed to reduce tight junction protein downregulation, promote beneficial intestinal bacteria proliferation, maintain acidic intestinal environment, and reduce intestinal permeability. The application indicates the composition may be used in foods, feeds, pharmaceuticals, or quasi-drugs for improving intestinal health and preventing or treating leaky gut syndrome, obesity, or metabolic diseases.
Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells
USPTO published patent application US20260097131A1 titled 'Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells.' The application (filed December 11, 2025) discloses compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo using non-viral delivery of polynucleotides encoding transcription factors. The patent application is now publicly available.
Reboxetine Patent Application for Narcolepsy and Cataplexy Treatment
USPTO published patent application US20260097040A1 by Herriot Tabuteau covering methods of treating narcolepsy with cataplexy using reboxetine or esreboxetine. The application includes pharmaceutical compositions and instructions for use in treating the condition. Filing date was December 11, 2025, with publication on April 9, 2026.
Methods for Treating Fatty Liver Disease (NASH) with Resmetirom
USPTO published patent application US20260097039A1 disclosing methods of treating fatty liver disease (non-alcoholic steatohepatitis/NASH) and improving liver fibrosis using resmetirom (2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile) or its pharmaceutical salts. Inventors: Rebecca Taub and Dominic Labriola. Application filed December 10, 2025, and published April 9, 2026. This is a publication of a patent application, not a granted patent.
Peptide Analogue for Treatment of Diabetes or Obesity
USPTO published patent application US20260097101A1 for a peptide analogue of pancreatic polypeptide (PP) intended for treating diabetes or obesity. Filed September 6, 2023 under application number 19110570, the invention also covers methods of treatment and use in manufacturing a medicament for these conditions.
Cancer Treatment Using Thyroid Hormone Analogs T2 and RT3
USPTO published patent application US20260097100A1 filed by Keith Roger Latham and Regina L. Garland on September 25, 2025, covering methods and compositions for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs such as T2 and RT3. The application discloses pharmaceutical compositions including topical formulations for skin cancer and delivery systems for systemic administration.
Arixtra Recall: Needle Iron Particle Discoloration in Pre-filled Syringes
BfArM issued a Drug Safety Communication regarding Viatris Healthcare Limited's Arixtra (fondaparinux sodium) pre-filled syringes. Reports indicate brown discoloration and blockage in needles caused by oxidized iron particles. Affected batches must not be dispensed or administered if discoloration is observed.
Phenhydan Injection: DHPC on Visual Particles, Filter Required
BfArM published an updated DHPC from Desitin Arzneimittel GmbH regarding Phenhydan solution for injection (phenytoin sodium), following particle contamination identified in batch 021950 during official sample analysis. The company clarified that a syringe filter with 0.2-0.45 µm pore size must be used when drawing up the solution, then removed before patient administration. This supersedes the November 2025 filter guidance which was corrected for accuracy.
Accupaque Visipaque Batch Risk Alert: Particle Contamination in Iohexol Iodixanol Solutions
GE Healthcare Buchler GmbH & Co. KG issued a Direct Healthcare Professional Communication (DHPC) alerting to a potential risk of particles in certain batches of Accupaque (iohexol) and Visipaque (iodixanol) solutions for injection filled into polypropylene bottles. The company instructs that only clear, particle-free solutions may be used per the Summary of Product Characteristics (SmPC), and this must be verified prior to administration.
Eberth Antibiotics - Outdated Package Inserts Create Patient Safety Risk
Dr. Friedrich Eberth Arzneimittel GmbH issued a Direct Healthcare Professional Communication (DHPC) via BfArM alerting that certain batches of nine antibiotic and antifungal products have outdated package inserts, creating a potential patient safety risk. Affected products include multiple strengths of cefazolin, cefotaxime, ceftazidime, ceftriaxone, levofloxacin, moxifloxacin, and voriconazole. Healthcare professionals are advised to discard outdated package inserts and refer to the current package inserts provided with the communication.
Mysimba Cardiovascular Risk and Annual Assessment Requirements
BfArM, in agreement with EMA, issued a Direct Healthcare Professional Communication regarding Mysimba (naltrexone/bupropion). The communication addresses long-term cardiovascular risks that have not been fully determined for patients treated beyond one year. New recommendations include discontinuation of treatment after one year if patients have not maintained at least 5% weight loss, and mandatory annual cardiovascular risk assessments for treatment continuation decisions.
ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
The USPTO published patent application US20260098078A1 covering activin receptor type II chimera polypeptides for treating conditions involving muscle weakness and atrophy, bone damage, blood disorders such as anemia, thrombocytopenia, and neutropenia, as well as fibrosis, metabolic disorders, and pulmonary hypertension. The application describes extracellular ActRII chimeras optionally fused to Fc domains as therapeutic agents.
Protein Crystallization Method, Multiple Protein Feeds
Protein Crystallization Method, Multiple Protein Feeds
High-Purity Recombinant Human Albumin Preparation Method
Tonghua Anrate Biopharmaceutical Co., Ltd. has filed USPTO Patent Application US20260098079A1 for a method of preparing high-purity recombinant human albumin using medium-long-chain fatty acid ligands and ion exchange chromatography. The application discloses a process where oleic acid, myristic acid, sodium palmitate, and sodium stearate are combined with recombinant human albumin in defined molar ratios with poloxamer to achieve high stability and purity through sequential anion and/or cation chromatography to remove truncated and modified albumins.
Modified Protein Scaffold Patent by Evolveritas
The USPTO published patent application US20260098080A1 for a modified protein scaffold comprising amino acid sequence SEQ ID NO: 115 with specific amino acid modifications in defined positions. The application was filed by Evolveritas Biotechnológiai Korlátolt Felelősségű Társaság, a Hungarian biotechnology company, with eight named inventors. The claimed protein scaffold includes segment formula Ih-mod GX1CX1VX2X3X4X5 and is intended for pharmaceutical preparations, kits, and screening procedures.
CD7 Antibody Antagonists for Therapeutic Applications
USPTO published patent application US20260098089A1 titled 'CD7 Antibody Antagonists for Therapeutic Applications' filed September 8, 2025 by inventors E-Chiang Lee, Gwenoline Borhis, Cassandra Van Krinks, Lucy Hepburn, Luke Bayliss, and Miha Kosmac. The application covers Cluster of Differentiation 7 (CD7) antibody antagonists and fragments for therapeutic uses, including methods, uses, and combinations. Patent applications establish priority dates and filing status but do not yet grant enforceable intellectual property rights.
HIV/HBV Treatment Using CD8-Targeting Fusion Proteins
USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.
Cμ4 Region for Multi-Specific Antibody Chain Pairing
USPTO published patent application US20260098094A1 assigned to DNA Twopointo, Inc. covering multi-specific antibodies with IgM Cμ4 region pairing domains for correct heavy and light chain pairing. The invention promotes correct chain combinations and disfavors incorrect pairings in bispecific antibodies. The application was filed November 21, 2025.
Anti-CGRP Monoclonal Antibodies for Treating Nausea and Vomiting Including CINV
The USPTO published patent application US20260098082A1 for methods using anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies to treat nausea and vomiting, including chemotherapy-induced nausea and vomiting (CINV). The application, filed September 13, 2023, claims methods of preventing and counteracting CINV by targeting CGRP, a neuropeptide associated with emetic responses to chemotherapy and other triggers.
Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis US20260098088A1
USPTO published patent application US20260098088A1 assigned to Disc Medicine, Inc. The application covers anti-hemojuvelin (HJV) antibodies and methods for treating myelofibrosis and associated conditions. Inventors include Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, and Jennifer M. Perez. CPC classifications include C07K 16/28 and related antibody technology classes.
Flexible Elongate Device with Variable Bending Stiffness
USPTO published patent application US20260097185A1 titled 'Systems and Methods for Varying Bending Stiffness of a Flexible Elongate Device.' The application, filed September 18, 2023 under application number 19112852, discloses a flexible elongate medical device comprising an articulable distal section and a non-articulable proximal section with varying bending stiffness along its length. Inventors are Rumen Deyanov and Russell Field.
Steerable Catheter Articulation State Indicator Patent
Steerable Catheter Articulation State Indicator Patent
Guide Element for Intravascular Access Device - Patent Application US20260097186A1
USPTO published patent application US20260097186A1 for a guide element for intravascular access devices. The invention includes a needle inside a catheter lumen with a working space configured to receive tools, and a guide element with annular elements to control its distal end. The application was filed on September 20, 2023, under application number 19113880.
Guidewire with Multi-Edge Profile for Enhanced Torque and Reduced Friction
USPTO published patent application US20260097187A1 for a guidewire with a multi-edge profile designed to improve torque transmission and reduce friction during intravascular navigation. The application includes helical configurations with discrete peaks and valleys, variable pitch sections, and polymer jackets with hydrophilic coatings. The system may include diagnostic catheters deliverable simultaneously with main catheters without additional support.
Neuravi Catheter Navigation Device Minimizes Vessel Bifurcation Catching
USPTO published patent application US20260097189A1 for Neuravi Limited, filed October 9, 2024, covering an endovascular navigation device for use with funnel catheters. The device features a radially expandable section positioned between a tapered distal section and proximal section, designed to prevent the free terminating distal edge of a funnel catheter from catching at bifurcated vessels during navigation. The expandable section expands to match the catheter's maximum inner diameter when deployed. The invention addresses complications in catheter procedures at vessel bifurcations.
Multifunction Skin Treatment Device With Detachable Heads, Auto-Detection, Serum Application
USPTO published Application US20260097193A1 for a multifunction skin treatment device with detachable treatment heads, automatic function detection, and integrated serum application. Invented by Shaul Rappaport, the device enables releasable attachment of various function heads for different treatments and a skin serum vial. The device automatically detects the attached function head type and adjusts operation accordingly, and also detects when a serum vial is fluidly connected.
Protective Assembly for Sensors in Medical Devices
USPTO published patent application US20260098776A1 for a protective assembly for sensors in medical devices. The invention comprises a substrate with an enclosing port containing electronic components wire-bonded to the substrate, covered by gel material and a fluoropolymer polyimide film (FEP). Medical device manufacturers developing sensor technologies should review this patent for potential overlap with their own IP portfolios.
Cochlear Implant Lead Insertion Site Access System and Methods
USPTO published patent application US20260097191A1 for a system and methods for accessing a cochlear implant lead insertion site under direct visualization. Inventors Hugo Peris, Benson Jung, and Kevin W. Sacherman filed the application on December 12, 2025. The system enables delivery of formulations to the middle ear and cochlear implant lead insertion sites.
Electronic Emulsion Release Device with Microneedle Transdermal Delivery
The USPTO published patent application US20260097192A1 for an electronic device for releasing emulsion using microneedle transdermal delivery technology. The application was filed by KT & G Corporation and covers a device including a cartridge accommodation part, crushing circuit, processor, transfer circuit, and microneedle for discharging emulsion through the skin. The invention has CPC classifications primarily in A61M medical device technology.
Cells, Organs with Modified Genes for Xenograft Tolerance
Cells, Organs with Modified Genes for Xenograft Tolerance
Cre-Lox AAV Gene Therapy Reconstitution System for Large Gene Delivery
The USPTO published patent application US20260098279A1 for a Cre-Lox AAV gene therapy system enabling delivery of therapeutic genes up to 16kb using up to four adeno-associated virus vectors with sequence-specific recombination. The invention by inventor Seongjin Seo includes novel lox site embodiments for near-unidirectional recombination. Applications include treatment of genetic disorders such as IFT140-associated retinitis pigmentosa and other retinal degeneration conditions.
Low Dose Psilocybin in Foodstuff and Microbes for Same
USPTO published patent application US20260098286A1 by ATX PHARMERS LLC covering engineered microbes transformed with psilocybin genes under weak or medium-level promoters to produce low levels of psilocybin, with applications in microdose and sub-microdose foodstuff production. No compliance obligations or deadlines are imposed by this publication.
Compositions and Methods for Screening Mutations in Thyroid Cancer
The USPTO published patent application US20260098297A1 on April 9, 2026, disclosing methods for screening mutations in thyroid cancer to determine whether patients with indeterminate thyroid nodules should undergo diagnostic surgery. The application covers screening patient thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to thyroid cancer-related genes. Six inventors are named including Shih-Min Cheng, Joseph Catanese, and Andrew Grupe. Filing date was December 9, 2025.
Affinity Chromatography Column for Cell Binding
USPTO published patent application US20260098840A1 by TQ Therapeutics GmbH for a column design for affinity chromatography. The invention comprises a column body with a retention volume containing a stationary phase, open ends for cell addition/removal, and obstacles such as grids or pins. The application covers the column design, a system of columns, and methods for binding cells using the disclosed technology.
Patent: Acetyl Glucosamine Improves Cognition
Patent: Acetyl Glucosamine Improves Cognition
SGLT-2 Inhibitor Pharmaceutical Composition for Diabetes Treatment
The USPTO published patent application US20260097058A1 for a pharmaceutical composition containing SGLT-2 inhibitors for treating diabetes mellitus, impaired glucose tolerance, hyperglycemia, and metabolic disorders. Inventors include Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, and Rolf Grempler. The application was filed on December 11, 2025.
Antibacterial Compositions with Avermectin and Melatonin for Demodex Blepharitis Treatment
USPTO published patent application US20260097059A1 covering pharmaceutical compositions for treating Demodex blepharitis. The compositions include avermectin compounds (such as ivermectin derivatives) and melatonin, with optional concentrations under 1 wt %. The application also discloses wipe devices incorporating these treatment compositions. Inventor Rolando Toyos filed the application on January 30, 2025, with publication on April 9, 2026.
Implantable Pressure Sensor Method Described
Implantable Pressure Sensor Method Described
Implantable Pressure Sensor Arrangement for Electronic Implantable Device
USPTO published patent application US20260096889A1 for an implantable pressure sensor arrangement designed for electronic implantable devices. The invention features a metal housing with flexible metal diaphragm positioned in a fluid control system manifold, configured to convert fluid pressure into electrical signals. The application was filed on October 4, 2024, under application number 18906871.
Eye Implant Device with Arcuate Scaffold for Drug Delivery
USPTO published patent application US20260096927A1 for an aqueous humor outflow device featuring an arcuate scaffold for drug delivery. The arcuate scaffold extends continuously circumferentially and is sized to fit within the conventional aqueous humor outflow pathway of a mammalian eye. Inventors Douglas Cali and David Richardson disclosed that the scaffold contains docking stations or ports for retaining drug eluting or drug delivery implant devices.
Systems and Methods for Anchoring an Implant (US20260096812A1)
The USPTO published patent application US20260096812A1 titled 'Systems and Methods for Anchoring an Implant' filed by inventors Khairkhahan, Lesh, Klenk, Mar, Tene, and Tun. The application covers devices and methods for anchoring medical implants including anchors, sutures, clips, and tools. Filing date was September 23, 2025, with application number 19337424. The disclosed anchors could be utilized to secure cardiac implants such as coaptation assistance devices, annuloplasty rings, artificial valves, cardiac patches, sensors, pacemakers, mitral valve rings, or artificial mitral valves.
Minimally Invasive Glaucoma Surgery Device and Ocular Implant
USPTO has published patent application US20260096926A1 for a minimally invasive glaucoma surgery device and ocular implant by inventors Houfar Sekhavat and Nir Shoham-Hazon. The device is designed for office-based or operating room bleb forming procedures and includes a proximal segment for user grasping, a distal segment with a piercing member, and a pivot point mechanism allowing rotation between locked and unlocked configurations. The application was filed on October 24, 2025.
FDA Issues RFI on Digital Health Clinical Trials
FDA Issues RFI on Digital Health Clinical Trials
Long Anticipated Medicare Advantage Compliance Guidance Heightens Investor and Provider Scrutiny
HHS-OIG issued its Industry Compliance Program Guidance for Medicare Advantage Organizations (MA ICPG), the first such guidance in over 25 years. The voluntary, nonbinding guidance signals heightened enforcement priorities and serves as a compliance benchmark for plans, providers, and investors. In 2024, Medicare Advantage covered 54% of all Medicare enrollees with estimated government spending of $462 billion.
EU Pharma Package Reforms Drug Development, Animal Testing
A&O Shearman analyzes the EU Pharma Package reforms following the Council of the European Union and European Parliament's December 2025 trilogue agreement. The provisional texts include a new Regulation and Directive covering expanded scientific advice, a shift away from animal testing, new frameworks for platform technologies, faster marketing authorization pathways, and regulatory sandboxes. These reforms aim to reduce regulatory burden and accelerate authorization procedures for medicinal products addressing unmet medical needs.
2026 White Collar Year in Preview: Healthcare Fraud, FCA, HIPAA Enforcement
Foley Hoag LLP published its 2026 White Collar Year in Preview ebook analyzing anticipated enforcement trends across healthcare fraud, False Claims Act enforcement, HIPAA enforcement, SEC/CFTC/PCAOB priorities, anti-corruption, and international trade. The publication examines steady enforcement activity, evolving regulatory priorities, and significant court decisions expected to shape compliance and risk management strategies for organizations in 2026.
National Fraud Enforcement Division Shifts Healthcare Fraud Enforcement
On April 7, 2026, Acting Attorney General Todd Blanche issued a memorandum formally establishing the National Fraud Enforcement Division (NFED), consolidating DOJ's criminal fraud investigative capabilities under a single Assistant Attorney General. The NFED immediately vests operational control of the Criminal Division's Tax Section, Health Care Fraud Unit, and Market, Government, and Consumer Fraud Unit with AAG Colin McDonald. Organizations in healthcare, federal contracting, benefits administration, and trade fraud sectors face heightened federal enforcement scrutiny under the new structure.
CMS Greenlights Hemp Product Pilot for Medicare Beneficiaries
CMS launched the Substance Access Beneficiary Engagement Incentive pilot program on April 1, 2026, allowing healthcare providers participating in CMMI models to offer hemp products to Medicare beneficiaries. Products must be federally legal hemp-derived with no more than 0.3% delta-9 THC, limited to $500 per beneficiary annually. Providers must submit CMS-approved implementation plans and quarterly reports.
FDA's 2026 General Wellness Policy and What It Means for Manufacturers of Wearable Devices
Womble Bond Dickinson analyzes FDA's General Wellness Policy finalized January 6, 2026, which describes FDA's enforcement discretion approach for low-risk products marketed for general wellness purposes. The guidance establishes two key evaluation factors: whether the product's intended use is limited to general wellness, and whether it presents low risk to users and others. The article explains how FDA evaluates wearable devices that estimate physiological measures such as blood pressure, oxygen saturation, and heart rate variability.
FinCEN Advisory Warns Financial Institutions of Healthcare Fraud Targeting Medicare and Medicaid
FinCEN issued an advisory warning financial institutions to heighten scrutiny of transactions tied to healthcare fraud targeting Medicare, Medicaid, and other federal and state healthcare benefit programs. The advisory, coordinated with the FBI and HHS-OIG, identifies fraud schemes involving shell companies, stolen identities, false beneficial ownership, phantom billing, and money laundering through digital assets and real estate. Financial institutions supporting the healthcare industry and healthcare providers are advised to take proactive measures.
DOJ Civil Rights Investigations Target Medical School Admissions
The Department of Justice Civil Rights Division has initiated proactive civil-rights investigations into medical school admissions practices, requesting seven years of applicant-level data and internal communications by April 24, 2026. The investigations focus on potential race discrimination following the Supreme Court's 2023 decision restricting race-conscious admissions. Schools must produce test scores, zip codes, legacy/donor ties, DEI communications, and correspondence with pharmaceutical companies. These actions represent a significant expansion of federal oversight into graduate and professional education, complementing parallel Department of Education reporting initiatives.
Sixteen Landmarks Illuminated Blue and Green for National Donate Life Day
NY DOH announced that 16 landmarks across New York State will be illuminated in blue and green on April 10, 2026, in honor of National Donate Life Blue & Green Day. The initiative aims to raise awareness about organ, eye, and tissue donor registration. In 2024, more than 50 percent of eligible New Yorkers joined the Donate Life Registry, now at 52.9 percent. The NY Living Donor Support Program, launched October 2025, has received 124 applications with a 100 percent acceptance rate and nearly $215,000 reimbursed to living donor applicants.
State Landmarks Illuminated Blue for World Parkinson's Day
The New York State Department of Health announced that 16 state landmarks will be illuminated blue on the evening of April 11 in recognition of World Parkinson's Day. The landmarks include One World Trade Center, Niagara Falls, Grand Central Terminal, and other notable sites. Commissioner Dr. James McDonald encouraged individuals experiencing movement difficulties to consult healthcare providers for treatment options.